NASDAQ:SUPN

Supernus Pharmaceuticals Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy SUPN

*Your capital is at risk

$44.63

-0.98 (-2.15%)

At Close: Jul 31, 2026

Supernus Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -46.56. In total, the insiders bought 563.66K and sold 247.69K SUPN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-46.56
● Buy	563.66K shares
● Sell	247.69K shares
56% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Mar 02, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -46.56. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 25, 2026 Buy	Common Stock A-Award	Rubin Jonathan SVP, Chief Medical Officer	Officer	1 250 Value: $70.4K
Feb 25, 2026 Sell	Common Stock F-InKind	Rubin Jonathan SVP, Chief Medical Officer	Officer	675 Value: $34.2K
Feb 25, 2026 Sell	Restricted Stock Unit D-Return	Rubin Jonathan SVP, Chief Medical Officer	Officer	1 250 Value: $0
Feb 25, 2026 Buy	Common Stock A-Award	Bhatt Padmanabh P. Sr. Vp Of Ip, Cso	Officer	1 250 Value: $70.4K
Feb 24, 2026 Sell	Restricted Stock Unit D-Return	Bhatt Padmanabh P. Sr. Vp Of Ip, Cso	Officer	1 125 Value: $0
Feb 24, 2026 Sell	Common Stock F-InKind	Bhatt Padmanabh P. Sr. Vp Of Ip, Cso	Officer	581 Value: $29.8K
Feb 24, 2026 Sell	Common Stock F-InKind	Bhatt Padmanabh P. Sr. Vp Of Ip, Cso	Officer	354 Value: $18.0K
Feb 24, 2026 Buy	Common Stock A-Award	Bhatt Padmanabh P. Sr. Vp Of Ip, Cso	Officer	1 250 Value: $66.6K
Feb 24, 2026 Sell	Restricted Stock Unit D-Return	Barlow Carrolee Director	Director	4 475 Value: $0
Feb 24, 2026 Buy	Common Stock A-Award	Barlow Carrolee Director	Director	4 475 Value: $238.5K
Feb 24, 2026 Buy	Common Stock A-Award	Newhall Charles W Iii Director	Director	4 475 Value: $238.5K
Feb 24, 2026 Sell	Restricted Stock Unit D-Return	Dec Timothy C Senior Vice-president & CFO	CEO / President	500 Value: $0
Feb 24, 2026 Sell	Common Stock F-InKind	Dec Timothy C Senior Vice-president & CFO	CEO / President	603 Value: $31.0K
Feb 24, 2026 Sell	Restricted Stock Unit D-Return	Dec Timothy C Senior Vice-president & CFO	CEO / President	1 125 Value: $0
Feb 24, 2026 Sell	Common Stock F-InKind	Dec Timothy C Senior Vice-president & CFO	CEO / President	1 524 Value: $77.5K
Feb 24, 2026 Buy	Common Stock A-Award	Dec Timothy C Senior Vice-president & CFO	CEO / President	3 000 Value: $159.9K
Feb 24, 2026 Sell	Restricted Stock Unit D-Return	Dec Timothy C Senior Vice-president & CFO	CEO / President	3 000 Value: $0
Feb 24, 2026 Buy	Common Stock A-Award	Dec Timothy C Senior Vice-president & CFO	CEO / President	1 125 Value: $60.0K
Feb 24, 2026 Buy	Common Stock A-Award	Dec Timothy C Senior Vice-president & CFO	CEO / President	500 Value: $26.7K
Feb 24, 2026 Sell	Common Stock F-InKind	Dec Timothy C Senior Vice-president & CFO	CEO / President	242 Value: $12.3K
Feb 24, 2026 Sell	Restricted Stock Unit D-Return	Newhall Charles W Iii Director	Director	4 475 Value: $0
Feb 24, 2026 Buy	Common Stock A-Award	Hudson Frederick M. Director	Director	4 475 Value: $238.5K
Feb 24, 2026 Sell	Restricted Stock Unit D-Return	Hudson Frederick M. Director	Director	4 475 Value: $0
Feb 24, 2026 Sell	Common Stock F-InKind	Bhatt Padmanabh P. Sr. Vp Of Ip, Cso	Officer	646 Value: $32.9K
Feb 24, 2026 Buy	Common Stock A-Award	Bhatt Padmanabh P. Sr. Vp Of Ip, Cso	Officer	750 Value: $40.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SUPERNUS PHARMACEUTICALS

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy tr...

Read Full Profile Here